Creo Medical Group PLC

Creo Medical Group PLC has a liquidity ratio of 2.75, indicating a strong current asset coverage over current liabilities. The company's cash and equivalents amount to 8.7 million GBP, while its operating cash flow is negative at -22.2 million GBP, suggesting ongoing operational cash outflows. The debt-to-equity ratio is 0.1, reflecting a low leverage position with total liabilities of 22.6 million GBP against total equity of 42.4 million GBP. The company's profitability is currently negative, with a return on equity of -67.69% and a return on assets of -44.15%. This is driven by a net loss of 28.7 million GBP and an operating loss of 28.8 million GBP, despite a gross profit of 1.9 million GBP. These figures indicate that the company is not currently generating sufficient revenue to cover its operating costs and is experiencing significant losses. Creo Medical Group PLC operates in a single business segment focused on electrosurgical devices for endoscopy. The company's revenue is not disclosed by geographic region, but its operations are centered on the development and commercialization of its CROMA technology. The company's business is not diversified across multiple product lines or geographic markets, which may increase its exposure to market-specific risks. The company's growth trajectory is not currently positive, with a net loss of 28.7 million GBP and an operating loss of 28.8 million GBP. The company's revenue is 4.0 million GBP, and there is no indication of a significant increase in revenue in the near term. The company's capital expenditures are -0.4 million GBP, indicating a small outflow for capital investments. The company's risk assessment indicates low liquidity and low dilution risk. There are no immediate filing-based liquidity or dilution flags, and the company's capital structure is not currently under pressure from significant debt or equity issuance. The company's dilution potential is low, and there are no indications of near-term equity issuance or share buybacks. Recent events related to the company include the development and commercialization of the CROMA powered by Kamaptive technology. The company has not disclosed any recent filings or transcripts that would indicate significant changes in its business strategy or financial position.